Jazz Pharmaceuticals (JAZZ) – Research Analysts’ Recent Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Jazz Pharmaceuticals (NASDAQ: JAZZ) in the last few weeks:

• 8/28/2026 – Jazz Pharmaceuticals was given a new $299.00 price target by Royal Bank Of Canada.
• 8/26/2026 – Jazz Pharmaceuticals had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $277.00 price target on the stock.
• 8/26/2026 – Jazz Pharmaceuticals had its price target raised by Morgan Stanley from $283.00 to $322.00. They now have an “overweight” rating on the stock.
• 8/26/2026 – Jazz Pharmaceuticals was given a new $300.00 price target by Canaccord Genuity Group Inc..
• 8/26/2026 – Jazz Pharmaceuticals had its price target raised by Deutsche Bank Aktiengesellschaft from $287.00 to $300.00. They now have a “buy” rating on the stock.
• 8/26/2026 – Jazz Pharmaceuticals had its price target raised by Truist Financial Corporation from $264.00 to $281.00. They now have a “buy” rating on the stock.
• 8/26/2026 – Jazz Pharmaceuticals had its price target raised by Needham & Company LLC from $292.00 to $310.00. They now have a “buy” rating on the stock.
• 8/11/2026 – Jazz Pharmaceuticals had its price target raised by Morgan Stanley from $280.00 to $283.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Jazz Pharmaceuticals was upgraded by Weiss Ratings from “hold (c-)” to “buy (b-)”.
• 8/4/2026 – Jazz Pharmaceuticals had its “buy” rating reaffirmed by Deutsche Bank Aktiengesellschaft. They now have a $287.00 price target on the stock.
• 8/4/2026 – Jazz Pharmaceuticals had its price target raised by TD Cowen from $275.00 to $300.00. They now have a “buy” rating on the stock.
• 8/4/2026 – Jazz Pharmaceuticals was given a new $264.00 price target by Truist Financial Corporation. They now have a “buy” rating on the stock.
• 8/4/2026 – Jazz Pharmaceuticals had its “buy” rating reaffirmed by UBS Group AG. They now have a $315.00 price target on the stock.
• 8/4/2026 – Jazz Pharmaceuticals had its price target raised by Wells Fargo & Company from $285.00 to $300.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Jazz Pharmaceuticals was given a new $275.00 price target by Stifel Nicolaus.
• 8/4/2026 – Jazz Pharmaceuticals had its price target raised by Piper Sandler from $301.00 to $310.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Jazz Pharmaceuticals had its price target raised by Barclays PLC from $260.00 to $270.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Jazz Pharmaceuticals had its price target raised by JPMorgan Chase & Co. from $265.00 to $276.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Jazz Pharmaceuticals had its price target raised by Morgan Stanley from $245.00 to $280.00. They now have an “overweight” rating on the stock.
• 8/4/2026 – Jazz Pharmaceuticals had its price target raised by Robert W. Baird from $252.00 to $280.00. They now have an “outperform” rating on the stock.
• 8/4/2026 – Jazz Pharmaceuticals had its price target raised by Needham & Company LLC from $282.00 to $292.00. They now have a “buy” rating on the stock.
• 7/20/2026 – Jazz Pharmaceuticals had its price target raised by Needham & Company LLC from $255.00 to $282.00. They now have a “buy” rating on the stock.
• 7/16/2026 – Jazz Pharmaceuticals is now covered by Canaccord Genuity Group Inc.. They set a “buy” rating and a $290.00 price target on the stock.
• 7/16/2026 – Jazz Pharmaceuticals was upgraded by Canaccord Genuity Group Inc. to “strong-buy”.
• 7/14/2026 – Jazz Pharmaceuticals had its price target raised by Wells Fargo & Company from $265.00 to $285.00. They now have an “overweight” rating on the stock.
• 7/14/2026 – Jazz Pharmaceuticals had its price target raised by Barclays PLC from $253.00 to $260.00. They now have an “overweight” rating on the stock.
• 7/9/2026 – Jazz Pharmaceuticals had its price target raised by Deutsche Bank Aktiengesellschaft from $250.00 to $270.00. They now have a “buy” rating on the stock.
• 7/7/2026 – Jazz Pharmaceuticals had its price target lowered by Truist Financial Corporation from $256.00 to $254.00. They now have a “buy” rating on the stock.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, EVP Robert Iannone sold 76,921 shares of Jazz Pharmaceuticals stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $249.70, for a total transaction of $19,207,173.70. Following the completion of the sale, the executive vice president owned 65,686 shares of the company’s stock, valued at approximately $16,401,794.20. The trade was a 53.94% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bruce C. Cozadd sold 6,000 shares of the business’s stock in a transaction dated Monday, August 3rd. The shares were sold at an average price of $252.98, for a total value of $1,517,880.00. Following the sale, the director owned 360,682 shares in the company, valued at approximately $91,245,332.36. The trade was a 1.64% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 91,278 shares of company stock valued at $22,712,816 over the last three months. 4.10% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.